Company News: J&J nixes production of heart stent, Sanofi pairs with Audion

Share this article:

Johnson & Johnson company Cordis has announced that it will discontinue the development of the Nevo Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies that are more in patient demand. Cordis will also halt production of Cypher and Cypher Select Plus Sirolimus-Eluting Coronary Stents by the end of 2011, according to a release.

Recently rebranded big pharma Sanofi has announced a two-year research partnership with biopharma company Audion Therapeutics with the objective of developing potential treatments for hearing loss. The collaboration will utilize technology developed at the Massachusetts Eye and Ear Infirmary – one of the world's leading research facilities devoted to the study of hearing and deafness – for the optimization of small molecules by using a regenerative medicine approach.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters